Drugs / Balcinrenone
Trials 21
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 116 trials | ||||||
| Phase 1 | NCT07754331 | Aug → Dec 2026 expected | kidney failure | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT06979388 | May → Jul 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06651021 | Oct 2024 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06388616 | May → Sep 2024 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04798222 | Jun → Sep 2021 | heart failure | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04686591 | Dec 2020 → Feb 2021 | cardiovascular disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04469907 | Jun 2020 → Oct 2021 | impaired renal function disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03843060 | Feb → Apr 2019 | diastolic heart failure | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03804645 | Feb → Apr 2019 | heart failure | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03801967 | Jan → May 2019 | heart failure | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03682497 | Nov 2018 → Mar 2020 | heart failure | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT03450759 | Mar → Jun 2018 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03435276 | Feb → Jun 2018 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02560363 | Nov 2015 → Jan 2016 | — | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 1 | NCT02532998 | Sep → Dec 2015 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02484729 | Jul → Nov 2015 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT06350123 | May 2024 → May 2025 | chronic kidney disease | AstraZeneca | Completed | Met primary |
| Phase 2 | NCT05884866 | Jul 2023 → Dec 2025 | chronic renal failure syndrome, disorder of acid-base balance | Klinikum Nürnberg | Completed | No outcome recorded |
| Phase 2 | NCT04595370 | Jan 2021 → Sep 2023 | chronic kidney disease, heart failure | AstraZeneca | Completed | Missed primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT07624305 | Sep 2026 → Jul 2030 expected | chronic kidney disease | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06307652 | Apr 2024 → Apr 2027 expected | heart failure | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | balcinrenone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06651021 ↗ |
| Known as | AZD9977 | “The aim of this phase 1 trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone (previously AZD9977) in participants with severe renal impairment vs....” PMID 39962632 ↗ Feb 202513“Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.” NCT04798222 ↗ “AZD9977 is an oral, selective mineralocorticoid receptor (MR) modulator.” NCT03804645 ↗ |
| Known as | Balcinrenona | ChEMBL registry synonym — accepted as the source's own label CHEMBL3916929 ↗ |
| Modality | Small molecule | — CHEMBL3916929 ↗ |
| Route | Oral | “AZD9977 as oral suspension” NCT02484729 ↗ |
| Target | NR3C2 | “Mineralocorticoid receptor modulator” CHEMBL3916929 ↗ |